Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042

Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042 - Trial in Progress

New trial in progress enrollment information for advanced and recurrent endometrial cancer - Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042.

Description & Faculty

	Robert Coleman, MD, FACOG, FACS Chief Medical Officer Vaniam Group USA
	Floor Backes, MD Moderator Director of Clinical Research and Fellowship Director for the Division of Gynecologic Oncology The Ohio State University Wexner Medical Center James Comprehensive Cancer Center USA

Supported in part by

Summary

Availability:

On-Demand

Cost:

FREE

Create Account

Recommended

Moving Towards Personalized Therapy in Endometrial Cancer

Treatment options for patients with advanced or recurrent endometrial cancers are rapidly evolving. Dr. Vicky Makker shares recent report from ASCO 2024 on Selinexor, a novel oral maintenance therapy for patients with TP53 wild type advanced or recurrent endometrial cancer.

Free

Personalized Management of Advanced or Recurrent Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications

This course offers an in-depth exploration of personalized treatment approaches for endometrial cancers, focusing on proficient mismatch repair (pMMR), deficient mismatch repair (dMMR) diseases and molecular classification in the recurrent setting.

Free

Surgical Film Library

Curated film collection reviewed by global surgical experts showcasing gynecologic oncology surgery procedures and techniques. Films provide practical learning through surgical demonstrations.

Free

IGCS 2024 Endometrial Cancer Master Session

Held at the IGCS 2024 Annual Global Meeting in Dublin, Ireland on October 16, 2024.

Free

Redefining Platinum Sensitivity : Additional Treatment Considerations in a Changing Paradigm

Dr. Robert Coleman with moderation by Dr. Floor Backes and Dr. Wendel Naumman. Dr. Coleman explores the evolving treatment strategies for recurrent platinum-sensitive ovarian cancer, drawing on the latest clinical trial data and real-world outcomes.

Free

Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer

This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease.

Free

Refining Molecular Classification and Personalizing Therapy in Endometrial Cancer

Presented during the IGCS and AGOI webinar Uterine Cancers in the Molecular Era: Changing Trends and Implications. Recorded on June 23, 2025.

Free

From Data to Practice: Integrating Key Phase III Results into Ovarian Cancer Management

Kathleen Moore details outcome measures from three major phase III trials—KEYNOTE-B96, ROSELLA, and MIRASOL—highlighting objective response rates, progression-free and overall survival, and key safety signals.

Free

Genetic Testing for Lynch Syndrome in Endometrial Cancer

In this special IGCS podcast episode, we spotlight the United Kingdom’s groundbreaking National Lynch Syndrome Project and its free, globally accessible e-learning modules that equip healthcare professionals with the knowledge and skills to implement genetic testing for Lynch syndrome in gynecologic oncology.

Free

Uterine Cancers in the Molecular Era: Changing Trends and Implications

This 2-hour webinar will bring together international experts to explore evolving molecular insights, treatment trends, and clinical challenges in uterine cancer through lectures and a tumor board discussion.

Free